BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11118360)

  • 1. Alleviation of murine leukemia virus repression in embryonic carcinoma cells by genetically engineered primer binding sites and artificial tRNA primers.
    Modin C; Lund AH; Schmitz A; Duch M; Pedersen FS
    Virology; 2000 Dec; 278(2):368-79. PubMed ID: 11118360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine leukemia virus with a primer-binding site complementary to tRNALys,3 adapts to select new tRNAs for replication following extended in vitro culture.
    Palmer MT; McPherson S; Morrow CD
    Virology; 2005 Mar; 333(2):337-48. PubMed ID: 15721366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in both the U5 region and the primer-binding site influence the selection of the tRNA used for the initiation of HIV-1 reverse transcription.
    Kang SM; Wakefield JK; Morrow CD
    Virology; 1996 Aug; 222(2):401-14. PubMed ID: 8806524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The G490E mutation in reverse transcriptase does not impact tRNA primer selection by HIV-1 with altered PBS and A-loop.
    Xu W; Morrow CD
    Virology; 2006 Sep; 352(2):380-9. PubMed ID: 16781756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of murine leukemia virus replication complemented by yeast tRNA(Phe) reveals inherent preferences for the tRNA primer selected for reverse transcription.
    Palmer MT; Morrow CD
    Virology; 2004 Jul; 324(2):430-8. PubMed ID: 15207628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated primer binding sites interacting with different tRNAs allow efficient murine leukemia virus replication.
    Lund AH; Duch M; Lovmand J; Jørgensen P; Pedersen FS
    J Virol; 1993 Dec; 67(12):7125-30. PubMed ID: 7693968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the RNase H primer grip domain of murine leukemia virus reverse transcriptase decrease efficiency and accuracy of plus-strand DNA transfer.
    Mbisa JL; Nikolenko GN; Pathak VK
    J Virol; 2005 Jan; 79(1):419-27. PubMed ID: 15596835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of functional tRNA primers and primer binding site sequences from a retroviral combinatorial library: identification of new functional tRNA primers in murine leukemia virus replication.
    Lund AH; Duch M; Pedersen FS
    Nucleic Acids Res; 2000 Feb; 28(3):791-9. PubMed ID: 10637332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the interaction between tRNA and primer binding site from characterization of a unique HIV-1 virus which stably maintains dual PBS complementary to tRNA(Gly) and tRNA(His).
    Li Y; Zhang Z; Kang SM; Buescher JL; Morrow CD
    Virology; 1997 Nov; 238(2):273-82. PubMed ID: 9400600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
    Han W; Wind-Rotolo M; Kirkman RL; Morrow CD
    Virology; 2004 Dec; 330(1):221-32. PubMed ID: 15527848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers.
    Hansen AC; Grunwald T; Lund AH; Schmitz A; Duch M; Uberla K; Pedersen FS
    J Virol; 2001 May; 75(10):4922-8. PubMed ID: 11312366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementarity between 3' terminal nucleotides of tRNA and primer binding site is a major determinant for selection of the tRNA primer used for initiation of HIV-1 reverse transcription.
    Yu Q; Morrow CD
    Virology; 1999 Feb; 254(1):160-8. PubMed ID: 9927583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys).
    Wakefield JK; Wolf AG; Morrow CD
    J Virol; 1995 Oct; 69(10):6021-9. PubMed ID: 7545240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication.
    Li X; Mak J; Arts EJ; Gu Z; Kleiman L; Wainberg MA; Parniak MA
    J Virol; 1994 Oct; 68(10):6198-206. PubMed ID: 7521916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site.
    Kempler G; Freitag B; Berwin B; Nanassy O; Barklis E
    Virology; 1993 Apr; 193(2):690-9. PubMed ID: 8460481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotropic murine leukemia virus replication in human mammary epithelial cells and the formation of cytomegalovirus-promoter recombinants.
    Reuss FU; Heber R; Ploss A; Berdel B
    Virology; 2001 Dec; 291(1):91-100. PubMed ID: 11878879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 nucleocapsid protein zinc finger structures induce tRNA(Lys,3) structural changes but are not critical for primer/template annealing.
    Hargittai MR; Mangla AT; Gorelick RJ; Musier-Forsyth K
    J Mol Biol; 2001 Oct; 312(5):985-97. PubMed ID: 11580244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys).
    Das AT; Klaver B; Berkhout B
    J Virol; 1995 May; 69(5):3090-7. PubMed ID: 7707537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence variation of the human immunodeficiency virus primer-binding site suggests the use of an alternative tRNA(Lys) molecule in reverse transcription.
    Das AT; Klaver B; Berkhout B
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():837-40. PubMed ID: 9129656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 reverse transcription initiation: a potential target for novel antivirals?
    Abbink TE; Berkhout B
    Virus Res; 2008 Jun; 134(1-2):4-18. PubMed ID: 18255184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.